Two CDK4/6 inhibitors, palbociclib (Ibrance) and ribociclib (Kisqali) have received approval for listing on the PBS for the treatment of breast cancer. At its March 2018 meeting, the Pharmaceutical Benefits Advisory Committee recommended the listing of palbociclib or ribociclib in combination with a non steroidal aromatase inhibitor (letrozole or anastrazole) as initial endocrine-based therapy in ...
PBS listings for drugs for breast cancer, gastric and head & neck cancers
By Michael Woodhead
25 Apr 2018